Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease
Norway60 participantsStarted 2025-02-01
Plain-language summary
OBJECTIVES OF THE STUDY
1. Investigate whether there are just as few infusion reactions with infliximab infusions of 60 min and 30 min.
2. Investigate patient and nurse satisfaction with infusions of 60 min and 30 min.
3. Investigate resource use in terms of total length of stay and use of nursing resources.
Who can participate
Age range
1 Year – 18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Pediatric IBD patients on infliximab
* 1-17 years
* Received at least 5 infusions of infliximab prior to entry in the study
Exclusion Criteria:
* Receiving infliximab for non-IBD condition (reumatological or other causes)
* previous severe infliximab infusion reaction
* need for an interpreter
* heart failure with hemodynamic impact
* unwillingness to participate
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of infusion reactions with infliximab infusions given over 60 minutes compared to 30 minutes.
Timeframe: depending on patients infusion intervals; 4 weeks x8 = 32 weeks, 8 weeks interval x8 = 64 weeks. The estimated time frame to complete the study for all included patients is april 2026.